On Friday, Biogen Inc (NASDAQ:BIIB)’s shares declined -2.03% to $96.57.
Honeywell (HON) Process Solutions (HPS) declared a new multi-year agreement to provide comprehensive services and support for Lundin Norway, Norway’s fastest-growing upstream oil and gas company.
Honeywell’s new Assurance 360 program will assist Lundin achieve continual and optimal performance of its automation system at the Edvard Grieg field in the Utsira High area of the central North Sea.
Under the program, HPS will provide all necessary technology, processes and support for the system over the next four years, counting hardware refresh, software updates and upgrades, and remote support. Key performance indicators in the contract will allow Lundin’s administration to monitor delivery of the service, while dedicated program administration provides a single point of accountability for performance.
Honeywell International Inc. operates as a diversified technology and manufacturing company worldwide. Its Aerospace segment provides aircraft engines, integrated avionics, systems and service solutions, and related products and services for aircraft manufacturers and operators, airlines, military services, and defense and space contractors; and spare parts, and repair and maintenance services for the aftermarket.
ACE Limited (NYSE:ACE)’s shares dropped -1.49% to $100.16.
ACE Aviation Holdings Inc. (ACE) declared its results for the second quarter of 2015.
2015 Second Quarter Results
In the second quarter of 2015, ACE recorded a decrease in net assets in liquidation of about $115 million as a result of the distribution to the shareholders of ACE in the aggregate amount of $115 million which was paid on June 2, 2015 . Income for the quarter was about $24,000 , as a result of interest income earned during the quarter offset by administrative and other expenses.
As at August 28, 2015 , ACE’s only remaining assets comprise of cash in an aggregate amount of about $19 million.
Liquidation Process and Interim Distribution to Shareholders
Given the results of the claims process and the expiry of a noteworthy portion of the contingent obligations covered by proofs of claims filed in such process, the Liquidator declared on April 28, 2015 that it intended to seek Court approval for a distribution to shareholders of ACE in the aggregate amount of $115 million , or about $3.54 per common share of ACE. The Court approved such distribution at a hearing held on May 8, 2015 . The record date to determine shareholders entitled to receive the distribution was May 26, 2015 and the payment of the distribution was accomplished on June 2, 2015 .
Future distributions of ACE’s remaining net cash to its shareholders are subject to the expiration or settlement of any contingencies and there is no certainty as to the timing or amount of such distributions. The final distribution to shareholders and the cancellation of the shares of ACE will not occur until all remaining contingent liabilities are settled or otherwise offered for.
ACE Limited, through its auxiliaries, provides a range of property and casualty insurance and reinsurance products worldwide. The company’s Insurance North American P&C segment offers casualty insurance, environmental, inland marine, professional risk, disaster protection, vacant land and building, and claims and risk administration services; homeowners, automobile, valuables, umbrella liability, and recreational marine insurance; and wholesale excess and surplus lines property, casualty, environmental, professional liability, inland marine, and product recall coverages. Its Insurance North American Agriculture segment provides comprehensive multiple peril crop insurance and crop-hail insurance; and farm and ranch coverages, in addition to specialty P&C coverages for companies that manufacture, process, and distribute agriculture products.
At the end of Friday’s trade, Rowan Companies PLC (NYSE:RDC)‘s shares dipped -0.80% to $17.29.
Rowan Companies plc (“Rowan” or “Company”) (RDC) declared recently that Tom Burke, President and Chief Executive Officer, is planned to present at the Barclays CEO Energy-Power Conference in New York City on Wednesday, September 9, 2015, starting at 9:45 a.m. U.S. Eastern Time.
A live audio webcast of the presentation will be accessible in listen-only mode through Rowan’s website at www.rowan.com. Please connect to our website at least 15 minutes proceeding to the planned start of the presentation to register, download and install any necessary audio software. Shortly after the live webcast, an archived version will be accessible on the website for about 30 days following the event.
Rowan is a global provider of contract drilling services with a fleet of 32 mobile offshore drilling units, composed of 28 self-elevating jack-up rigs and four ultra-deepwater drillships. The Company’s fleet operates worldwide, counting the United States Gulf of Mexico, the United Kingdom and Norwegian sectors of the North Sea, the Middle East, North Africa, Southeast Asia and Trinidad. The Company’s Class A Ordinary Shares are traded on the New York Stock Exchange under the symbol “RDC.” For more information on the Company, please visit www.rowan.com.
Rowan Companies plc provides offshore oil and gas contract drilling services. It operates a fleet of 30 self-elevating mobile offshore jack-up drilling units, in addition to 3 ultra-deepwater drill ships. The company operates in the United States Gulf of Mexico, the United Kingdom, and Norwegian sectors of the North Sea, the Middle East, West and North Africa, Southeast Asia, and Trinidad. Rowan Companies plc was founded in 1923 and is based in Houston, Texas.
Biogen Inc (NASDAQ:BIIB), ended its Friday’s trading session with 0.21% gain, and closed at $302.26.
Biogen (BIIB) declared that the first patient has been enrolled in the Phase 3 clinical program for its investigational treatment aducanumab. The Phase 3 program comprises two global, placebo-controlled studies named ENGAGE and EMERGE, which are designed to evaluate the efficacy and safety of aducanumab in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease (AD).
“Since the initial readout of our Phase 1b study, we have accelerated our aducanumab clinical program so that we can more fully characterize and confirm the benefit-risk profile of this investigational treatment for Alzheimer’s disease,” said Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer at Biogen. “Understanding the urgency to find effective treatments for this devastating disease, we are excited that we have enrolled our first patient in the Phase 3 program and we continue to work with our colleagues around the world to advance the study of aducanumab.”
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohns disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
